Cargando…
Interleukin-6 and severe COVID-19: a systematic review and meta-analysis
BACKGROUND: Evidence links COVID-19 severity to hyper-inflammation. Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19. We, therefore, performed the present systematic review...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Libbey Eurotext
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530350/ https://www.ncbi.nlm.nih.gov/pubmed/32933891 http://dx.doi.org/10.1684/ecn.2020.0448 |